Tag: NASDAQ BNGO

Business

Optical Genome Mapping (OGM) Vs. Traditional Methods in the Analysis for Acute Lymphoblastic Leukemia, Bionano Genomics, Inc. (NASDAQ: BNGO) Reports

More often than not, autism spectrum disorder (ASD) and some neurodevelopmental disabilities require diagnostic testing to ascertain their treatment. Hence the need for genetic research by scientists and clinicians. To accelerate the activities surrounding the research Bionano Genomics, Inc. (NASDAQ: BNGO) recommends the use of optical genome mapping (OGM) with […]

Business

BioNano Genomics Inc (NASDAQ: BNGO) Visual Genome Charting discloses new Visions and Predictive Abilities

BioNano Genomics Inc (NASDAQ: BNGO) has announced that its visual genome charting has revealed its new visions and predictive abilities that it offered at the 2021 European Cytogenomics Conference (ECA).  Summary of the leukemia demonstrations at the ECA containing OGM  One of the climaxes from the session included Dr. Elena […]

Business

Bionano Genomics Inc. (NASDAQ: BNGO) Making Progress With Adoption Of Spahyr System In China

Bionano Genomics Inc. (NASDAQ: BNGO) has announced that it has made considerable progress with Spahyr System adoption in China for optical genome mapping through WeHealth Shanghai. WeHealth is a reproductive health genome analysis solutions provider. Bionanon presents at structural variations symposium.  The company announced the adoption during the Structural Variation […]

Business

BioNano Genomics Inc (NASDAQ: BNGO) Provides Diagnostic Testing

BioNano Genomics Inc (NASDAQ: BNGO) announced the reviewed studies by two peers from well-known clinicians and scientists from European Institutions, including Hospices Civils in Lyon, Radboud University Medical Center, the University Hospital of Clermont-Ferrand, Radboud University Medical Center was published in the American Journal of Human Genetics back-to-back. Two groups […]